Literature DB >> 22474176

Unmet medical need in infectious diseases.

Adam L Hersh, Jason G Newland, Susan E Beekmann, Philip M Polgreen, David N Gilbert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22474176      PMCID： PMC3404719          DOI： 10.1093/cid/cis275

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  2 in total

Review 1.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.

Authors:  Helen W Boucher; George H Talbot; John S Bradley; John E Edwards; David Gilbert; Louis B Rice; Michael Scheld; Brad Spellberg; John Bartlett
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

2.  Combating antimicrobial resistance: policy recommendations to save lives.

Authors:  Brad Spellberg; Martin Blaser; Robert J Guidos; Helen W Boucher; John S Bradley; Barry I Eisenstein; Dale Gerding; Ruth Lynfield; L Barth Reller; John Rex; David Schwartz; Edward Septimus; Fred C Tenover; David N Gilbert
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079
  2 in total
  15 in total

Review 1.  Development of novel antibacterial drugs to combat multiple resistant organisms.

Authors:  Matteo Bassetti; Elda Righi
Journal:  Langenbecks Arch Surg       Date:  2015-02-11       Impact factor: 3.445

Review 2.  Novel approaches are needed to develop tomorrow's antibacterial therapies.

Authors:  Brad Spellberg; John Bartlett; Rich Wunderink; David N Gilbert
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

3.  The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett.

Authors:  Brad Spellberg; David N Gilbert
Journal:  Clin Infect Dis       Date:  2014-09-15       Impact factor: 9.079

4.  The Infectious Diseases Society of America emerging infections network: bridging the gap between clinical infectious diseases and public health.

Authors:  Satish K Pillai; Susan E Beekmann; Scott Santibanez; Philip M Polgreen
Journal:  Clin Infect Dis       Date:  2014-01-07       Impact factor: 9.079

5.  Cell-based screen for discovering lipopolysaccharide biogenesis inhibitors.

Authors:  Ge Zhang; Vadim Baidin; Karanbir S Pahil; Eileen Moison; David Tomasek; Nitya S Ramadoss; Arnab K Chatterjee; Case W McNamara; Travis S Young; Peter G Schultz; Timothy C Meredith; Daniel Kahne
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-07       Impact factor: 11.205

Review 6.  Probiotics for the Management of Infectious Diseases: Reviewing the State of the Art.

Authors:  Cato Wiegers; Linda H M van de Burgwal; Olaf F A Larsen
Journal:  Front Microbiol       Date:  2022-04-28       Impact factor: 6.064

7.  Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens.

Authors:  J A Sutcliffe; W O'Brien; C Fyfe; T H Grossman
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

Review 8.  The future of antibiotics.

Authors:  Brad Spellberg
Journal:  Crit Care       Date:  2014-06-27       Impact factor: 9.097

9.  Bacteriological profiling of diphenylureas as a novel class of antibiotics against methicillin-resistant Staphylococcus aureus.

Authors:  Haroon Mohammad; Waleed Younis; Hany G Ezzat; Christine E Peters; Ahmed AbdelKhalek; Bruce Cooper; Kit Pogliano; Joe Pogliano; Abdelrahman S Mayhoub; Mohamed N Seleem
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

10.  A Novel Topical Combination Ointment with Antimicrobial Activity against Methicillin-Resistant Streptococcus aureus, Gram-Negative Superbugs, Yeasts, and Dermatophytic Fungi.

Authors:  Kenneth S Thomson; Gina K Thomson; John Biehle; Andrew Deeb; Jamaal Crawford; R Herrera
Journal:  Curr Ther Res Clin Exp       Date:  2016-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.